Vylor (Seed) / New Corteva

Snapshot Across Reports

Pre-Spin Analysis — August 2026

Written August 22, 2026, against the August 21 close of $81.79. Primary source: the Form 10-12B/A information statement filed August 14, 2026 — the first amendment to the June 29 original, and the document that resolves the grade’s outstanding question. Secondary: Q2 2026 results, July 30.

Corteva splits in two on or about October 1, 2026. The seed and genetics business becomes Vylor Inc.; the crop protection business keeps the Corteva name and, with it, the CTVA ticker. Corteva shareholders keep their existing shares and receive Vylor shares on top.

The July 31 report graded this A−, provisional, because the original Form 10 left four blanks: Vylor’s debt, its cash distribution to the parent, the distribution ratio and the record date. The August 14 amendment fills the two that matter and leaves the two that don’t.

The thing that isn’t obvious from the headline

Read the transaction description and you would say Corteva is the parent and Vylor is the spinoff. Legally, that is correct. For accounting purposes it is backwards, and the filing says so in terms.

“Notwithstanding the legal form of the spin-off … for accounting and financial reporting purposes, Corteva’s Crop Protection Business will be presented as being spun-off from Corteva (the reverse of its legal form — a ‘reverse spin’) … Corteva best represents the predecessor entity to Vylor.”

Under ASC 505-60, when the legal spinnee is the larger business, it becomes the accounting spinnor — the successor. Vylor is ~65% of segment profit, so Vylor inherits Corteva’s audited history and Crop Protection is presented as the thing being disposed of.

Three consequences:

1. Vylor lists with seven years of audited financials. A normal spinco arrives with carve-out statements assembled for the occasion, and part of the day-one discount prices that opacity. Vylor arrives with Corteva’s actual consolidated history plus supplemental Seed carve-outs. The usual information asymmetry is smaller here than in almost any spinoff we track.

2. The remaining company is the one with something to prove. New Corteva keeps the name, the ticker and the index seat, and is simultaneously the smaller, lower-margin, structurally-pressured half. 06_spinoff_categories.md argues that a RemainCo in a breakup is “effectively a spinoff too.” Here GAAP says so in writing.

3. Our own price series for CTVA silently changes meaning on October 1. Same ticker, same legal entity, same CIK — and from that date it measures a $7.5B crop protection company rather than a $17.4B combined one. A continuity break without a ticker break, which no existing guard will catch.

What the amendment actually filled in

Two notes on the fine print. The $3,560M is an estimate in the pro forma notes, not a contractual figure — the Separation and Distribution Agreement description still reads “Vylor will distribute approximately $ to New Corteva.” And the Applicable Percentage remains blank, which matters more than it looks: it governs how shared environmental liabilities and any legacy liability that cannot be assigned to either business get split between the two companies.

Vylor’s capital structure at October 1, 2026:

Long-term debt is $1,280M of Vylor Notes — exchanged out of EIDP’s existing 2030s, 2032s and 2033s at a 4.12% weighted average, assuming 80% of holders tender — plus $1,156M from a delayed-draw term facility or new issuance. The short-term balance is seasonal, and the filing is explicit that working capital is higher at the October spin date than it was at June 30.

Net debt of $4,479M against FY26E EBITDA of roughly $2.75B is 1.63×; against FY25 pro forma EBITDA of $2,503M, 1.79×. Both struck at a seasonal peak in borrowings. Vylor targets investment grade and should get it.

Where management is going

The entire incumbent Corteva C-suite goes to Vylor. Not most of it — all of it, and the filing states the separation twice, in unusually absolute terms:

“After the spin-off, none of our executive officers will be executive officers of New Corteva.”

“While some of these individuals currently serve as employees or directors of Corteva, after the spin-off, none will serve as an employee or director of New Corteva.”

Vylor’s board will be seven members, six independent.

New Corteva hired from outside. Luke Kissam was named CEO of the crop protection company in April 2026 and joined on June 1. He was chairman, president and CEO of Albemarle until retiring in 2020, and before that held senior legal roles at Albemarle, Merisant and Monsanto.

This is the single clearest signal in the transaction. The management team that knows the combined business chose the seed side, unanimously and without a single crossover appointment. The crop protection company had to recruit a retired specialty-chemicals CEO with a legal background to run it — a coherent hire for a business whose job includes managing legacy liability and a structurally pressured end market, but not the profile of someone brought in to grow something.

Read alongside the liability allocation below, the pattern is consistent: the people and the assets went one way; the history went the other.

The two businesses — and what the revenue line reveals

Corteva reported Q2 on July 30. It beat on earnings, raised full-year guidance — and fell 11.9% the next session on 2.8× average volume, on revenue of $6.38B against roughly $6.6B expected. Adjusted EPS was $2.30 against $2.22.

Seed sales were flat and crop protection fell 3.8%. But the honest reading is not “the selloff was the half that stays behind” — Seed was expected to grow and did not. Volume fell 3%, offset by 3% price.

Now put three years of Seed alongside each other, which is where it gets interesting:

Revenue has barely moved. All of the earnings growth is margin. A 2.2% top-line CAGR does not, on its own, support a premium multiple, and the first draft of this analysis treated that as the central risk.

It is not, and the filing explains why. Vylor is deliberately converting a seed-selling business into a trait-licensing business:

“We are executing a strategic transition from being a net licensee of technology to becoming a leading net out-licensor … For 2025, we had gross out-licensing income and net royalty cost of $317 million and $439 million, respectively. We anticipate achieving royalty neutrality in 2026 and expect to grow into a $1.0 billion net royalty income position by 2035.”

That reframes the flat revenue line entirely. Licensing a trait instead of selling the bag reduces revenue and raises margin — and the 2025 commentary says exactly that, citing “the shift to an out-licensing model for soybeans in Brazil” as a volume drag and “increased out-licensing income” as a price/mix gain, in the same sentence.

The swing is large:

A $1.44B swing, against FY25 Seed EBITDA of $2,423M — roughly 59% of today’s earnings, at close to 100% incremental margin. It also explains the $610M Bayer settlement in January 2026, which terminated the Enlist E3 soybean royalty obligations, and why “reductions in net royalty expense” appears in every single EBITDA bridge in the document.

The caution is that these are two indistinguishable stories for two or three years. A deliberate high-margin mix shift and a mature business buying margin with cost cuts and one-time royalty relief look identical from outside. The difference shows up in whether out-licensing income keeps compounding after the cost actions anniversary — and the near-term test is checkable: did royalty neutrality actually arrive in 2026? That lands in the FY26 results, months after the spin.

Full-year guidance was raised to $4.1–4.3B operating EBITDA (~9% growth at the midpoint) and $3.60–3.80 operating EPS (~11%). Separation dis-synergies were cut from an initial $100M estimate to $25M.

Competitive Dynamics

The filing names its rivals in one sentence — “Our key competitors include BASF, Bayer, and Syngenta, as well as regional seed companies” — and then says something more revealing about the industry it operates in:

“While the industry is evolving rapidly, the time and cost to launch new products has only increased, with biotech traits taking approximately 16 years to commercialize.”

Sixteen years is the competitive analysis in a single number. It sets the barrier to entry, explains why the same four companies have held the field for two decades, and — as set out in §5 below — is also why the patent expiry schedule matters more than anything else on this page.

1. Crops, brands and competitive position

2. Market concentration — a durable duopoly

✅ The US row-crop seed market is one of the most concentrated in any industry. Bayer and Corteva together sell 72% of US corn seed and 66% of US soybean seed; the top four control 84% and 78% respectively. Vylor holds roughly 30–32% of the North American corn and soybean seed market, close to level with Bayer.

✅ Barriers are structural, not merely large. A new entrant needs (1) a germplasm library assembled over decades — Vylor claims the largest in the world, spanning more than ten crops; (2) ~16 years and hundreds of millions per biotech trait; (3) regulatory approval in every jurisdiction where the grain may travel; and (4) a route to the farmer. No one has cleared all four since the 1990s.

⚠️ The whole sector is unbundling at once, which is new. Within roughly twelve months: Corteva splits (October 1), Bayer is exiting the glyphosate business it inherited from Monsanto, Syngenta — wholly owned by China’s Sinochem — is preparing a Hong Kong IPO for Q4 2026, and BASF is reviewing a listing of its agricultural unit.

Four of four majors are restructuring simultaneously. For Vylor this cuts two ways: it validates the strategic logic, and it means Vylor will not be the only newly-listed pure-play ag equity competing for the same investor attention in 2026–27.

3. Moats and weak spots

✅ Strongest moat: the Pioneer direct sales channel. Vylor is the only major that reaches farmers through its own agents rather than through retail. The filing describes a model that “walks the acre,” with agents meeting farmers face-to-face across the season and relationships that “extend over multiple generations.” Bayer, Syngenta and BASF sell through dealers, co-ops and retailers. This is the asset a competitor genuinely cannot buy — and it is what lets Vylor introduce test concepts to farmers years before launch and harvest demand signal that rivals see only at order time.

✅ Strong moat: germplasm. Traits get licensed and eventually expire. Germplasm — the underlying genetics the trait is inserted into — does not. It compounds with every breeding cycle, and Vylor’s is the largest pool in the industry. This is the reason the business survives a patent cliff at all.

✅ Strong moat: dual-brand channel coverage. Pioneer premium/direct; Brevant premium/retail outside the US; plus country-specific brands. Vylor can serve the direct farmer and the retail farmer without cannibalising either.

⚠️ Weak spot: revenue growth is not the engine. Seed revenue compounded 2.2% over two years while EBITDA compounded 13.1%. Margin is doing all the work — which is fine while the mix shift runs, and a problem the moment it stops.

⚠️ Weak spot: Vylor is still a net licensee. The filing confirms it “holds multiple long-term biotechnology trait licenses from third parties” and that seed sold to customers “can contain biotechnology traits licensed from third parties.” The 2025 net royalty cost of $439M is that dependency priced. The strategy is to invert it — but the inversion is not complete.

⚠️ Weak spot: extreme seasonality and direct-channel exposure. 75% of sales and substantially all profit land in the first half. And the filing concedes that “our direct distribution channel … is more affected by planting delays than our competitors.” The moat has a weather beta attached.

❓ Emerging threat: gene editing lowers the 16-year barrier. CRISPR multiplexing platforms — Inari’s SEEDesign edits up to 10 genomic targets simultaneously, at a ~$700M Series D valuation — target the trait-development timeline that protects the incumbents. Vylor is itself investing here (gene editing plus internally developed AI, and its One Seed analytics platform). But a technology that compresses trait development from 16 years to five erodes the deepest moat in the industry, and the incumbent with the largest germplasm library has the most to lose from traits becoming cheap.

4. Head-to-head: Bayer Crop Science

⚠️ Bayer is the only competitor operating at Vylor’s scale across the same crops and geographies.

How Vylor won soybeans, and why that matters now. Bayer’s own 2025 report attributes its −7.7% soybean seed and traits decline to “the cancellation of the registration of dicamba-based products in the United States.” A US District Court vacated the over-the-top dicamba registrations in February 2024, leaving Bayer’s XtendFlex system without its companion herbicide for two seasons. Enlist E3 — built on 2,4-D choline, which never had the same volatility problem — took the acres.

⚠️ Both of those tailwinds are now reversing.

• Dicamba came back. The EPA re-registered Engenia, Tavium and Stryax (Bayer’s renamed XtendiMax) in February 2026 — though only for the 2026 and 2027 seasons, with mitigation requirements. The relief is real but expressly temporary.
• Bayer won at the Supreme Court. On June 25, 2026 the Court held 7–2 in Monsanto v. Durnell that FIFRA preempts state-law failure-to-warn claims where the EPA has made a definitive safety determination. Combined with the $7.25B class settlement — final approval hearing September 14, 2026, two weeks before Vylor lists — the overhang that has constrained Bayer’s crop science investment for eight years is lifting.

The honest framing: Vylor’s soybean share was won partly on merit — the A-Series Enlist E3 varieties show a 3 bu/ac advantage over XtendFlex across 2,462 comparisons with a 71% win rate — and partly on a competitor fighting a regulatory and legal fire. The fire is being put out. A re-capitalised, less distracted Bayer with a working dicamba label is a materially harder opponent than the one Corteva has faced since 2019, and Vylor meets it in its first year as a standalone company.

5. Crown jewel: the trait licensing franchise — and its expiry date

✅ The licensing business is the strategic center of the company. It converts R&D into royalty income earned on acres Vylor does not plant and seed it does not sell — participating “economically in seed markets beyond our branded footprint.” Margins approach 100% incrementally and cash conversion is high.

✅ The patent estate behind it is substantial: ~5,300 US patents, ~2,500 active outside the US, ~2,000 pending applications and ~2,000 trademark registrations.

⚠️ But the estate is front-loaded, and the filing discloses the schedule:

More than half the US estate expires within ten years. And the filing is specific about which ones:

“The patents related to certain Enlist® corn and soy biotech traits are set to expire beginning in 2031 through 2032. Patents related to our Qrome® technology … expire in 2032. Patents with respect to our next generation corn and soy biotechnology traits generally are set to expire in the 2040s.”

⚠️ This is the single most important thing on the page, and it is easy to miss. Enlist E3 — the trait that took soybean leadership, that the $610M Bayer settlement was fought over, and that underwrites today’s royalty economics — comes off patent in 2031–2032. The $1.0 billion royalty target is for 2035.

The target therefore does not depend on the franchise Vylor has. It depends on the one it has not yet commercialised. Getting from here to $1B of net royalty income requires a clean generational handoff to the next-generation traits — the ones with 2040s patents — and management has named the milestones: triple-stack corn traits available for out-licensing “as early as 2027” and third-generation above-ground insect traits in corn “by the end of the decade.”

Those two dates are the real test of the thesis, and both fall inside a normal holding period. The 2026 royalty-neutrality milestone tells you the current franchise is working. The 2027 triple-stack availability tells you whether the next one will be.

6. Total addressable market

⚠️ The global seed market is roughly $66–70B, growing to a projected $107–130B by the mid-2030s (~6% CAGR). Corn alone is about 36% of commercial seed revenue.

✅ Note what out-licensing does to the addressable market: it lets Vylor earn on acres planted with competitors’ seed. That is a genuine TAM expansion rather than a share fight, and it is why the strategy is worth more than the flat revenue line suggests.

7. Geographic and customer map

The Seed business reports two segments, and the concentration is severe:

¹ Segment EBITDA is struck before R&D and corporate expense, so the two do not sum to the $2,423M company figure. FY25: $3,413M less ~$995M of R&D ≈ $2,418M.

✅ The Americas are 80% of sales and 82% of segment profit — and essentially all of the margin expansion. The +360bp in the Americas against +100bp in the Rest of World says the mix shift to licensing and the price-for-value strategy are working where Pioneer’s direct channel is strongest, and much less elsewhere.

⚠️ That concentration is the real geographic risk. A US or Brazilian acreage shock, a Midwest weather year, or a corn-to-soybean rotation swing hits four fifths of the business at once. The Rest of World segment is too small and too slow-growing to offset it — 2.2% cumulative revenue growth across three years, with EMEA drought and Turkish Lira and Indian acreage swings as the recurring drags.

⚠️ Customer credit is a live line item. Vylor finances its own seasonal sales, and “higher bad debt expense” appears in both the 2024 and 2025 SG&A walks. Direct distribution means Vylor carries farmer credit that a retail-channel competitor pushes onto the distributor.

✅ Employees: approximately 12,300, about 11% represented by unions or works councils — a light labor footprint for the revenue base, consistent with a business whose costs are R&D and germplasm rather than manufacturing.

What the competitive picture means for the thesis

Three findings, in order of consequence:

1. The moat is real but its composition is shifting. Germplasm and the direct channel are durable. The trait patents are not — and the trait patents are what the 2035 royalty target monetises.
2. The competitive tailwind is turning into a headwind. Bayer spent 2019–2025 losing soybean share to a deregistered herbicide and a $7B+ litigation overhang. Both are resolving within weeks of the spin.
3. The checkable milestones are close. Royalty neutrality in 2026; triple-stack corn out-licensing in 2027. An investor does not have to wait until 2035 to learn whether this works.

Net assessment: the business is stronger than its competitive momentum

✅ On the durable factors, the picture is clearly positive. The germplasm pool is the largest in the industry and compounds rather than expires. The Pioneer direct channel cannot be bought or replicated. The 16-year trait cycle keeps the field to four players. Margins run 24.5% against Bayer Crop Science’s 19.4%, the balance sheet is clean at 1.6–1.8×, and there is no legacy litigation. Nothing found here argues against the quality of the asset — and the management migration points the same way.

⚠️ But on the factors that produced the recent outperformance, it is negative, and the timing is unkind. Vylor’s competitive position today is the best it has ever been — soybean trait leadership, record Americas margins, +360bp in a year. Both of the forces that delivered that are reversing in the same quarter the company lists. Dicamba returned in February 2026, and Bayer won at the Supreme Court on June 25 with its $7.25B settlement due for final approval on September 14 — sixteen days before Vylor begins trading. Bayer’s soybean business fell 7.7% in 2025 because it was fighting a fire. The fire is out.

And the asset that monetises the position has a disclosed expiry inside a normal holding period. Enlist E3 comes off patent in 2031–2032; the $1.0B royalty target is for 2035.

❓ One nuance keeps this from being worse than it looks. A patent cliff in seed is not a patent cliff in pharma. When a drug goes generic, revenue collapses. When a seed trait expires, the germplasm it is bred into stays proprietary, the brand and the channel remain, and hybrid corn does not breed true — farmers buy new seed every season regardless. The cliff threatens the $1B royalty ambition, not the $9.9B seed business.

The verdict is therefore split, and the split is the useful part. The core franchise is a net positive, durable enough to own. The growth narrative — the part that would justify paying a premium — is a net negative on the evidence, because it rests on royalties from traits that expire before the target date, and on share won partly from a competitor who was temporarily incapacitated.

That is the same conclusion the valuation section reaches by an entirely different route. Two independent analyses — one on multiples, one on competitive position — arriving at good asset, full price is worth more than either alone.

The falsifiable version, so this can be marked right or wrong: if Bayer’s soybean seed revenue returns to growth in FY2026 or FY2027 with dicamba back on label, the tailwind reading is confirmed. If Enlist holds ≥55% of acres anyway, the share was won on merit and this section was too cautious. That resolves within about eighteen months.

Where the liabilities go

For a business with chemical-industry ancestry this is the question that governs everything else, and the filing answers it cleanly. The legacy liabilities stay with New Corteva.

The operative language, from the risk factors:

"New Corteva will retain certain liabilities to the extent Corteva is responsible under the Prior Transaction Agreements, including obligations relating to historical PFAS and other environmental liabilities associated with legacy EIDP businesses, other than any such liabilities that are primarily related to the Seed Business."

And the mechanism, from the Separation and Distribution Agreement:

“New Corteva will have, on behalf of us and our subsidiaries … sole and exclusive authority to … defend … settle … all matters whatsoever … If we or any of our subsidiaries incur any indemnifiable losses … New Corteva will be required to indemnify us for all such indemnifiable losses.”

Two structural facts make this stick. EIDP, Inc. — formerly E. I. du Pont de Nemours and Company, the entity that carries the legacy DuPont obligations — remains a subsidiary of New Corteva. And Pioneer Hi-Bred, the seed business, is lifted out of EIDP and into Vylor before the distribution. The legacy vehicle and the clean asset are separated by design.

What New Corteva is keeping

What Vylor is taking

Vylor’s own “Environmental and Other Legal Proceedings” section is two matters and a boilerplate paragraph:

• AltEn, Mead, Nebraska — an ethanol plant that took treated seed as feedstock. Vylor is one of six seed companies in a voluntary cleanup group; an accrual is established for its share.
• AZ Concordia, Chile — a reservoir embankment collapsed in February 2026, flooding government infrastructure. Being resolved with local authorities.

Followed by: “our management does not anticipate that the ultimate disposition of these matters will have a material adverse effect.”

Why this reframes the $3.56 billion

The July report described the structure as “Vylor levers up to pay the parent,” which reads as value extraction — and on the numbers alone it is: Vylor borrows $5.6B and hands $3.56B to New Corteva.

But New Corteva is the entity keeping a ~$600M PFAS obligation, ~$624M of indemnification assets exposed to Chemours’ solvency, an active chlorpyrifos docket and a settled-but-unapproved antitrust matter — while owning the smaller, lower-margin, price-pressured business. Seen that way, the cash distribution is much less like extraction and much more like capitalising the entity that is keeping the history.

That is not a charitable reading; it is the one the structure supports. And it carries a warning for Vylor holders that the indemnity language does not fully dispose of: an indemnity is only as good as the indemnitor. Vylor’s protection from PFAS runs through New Corteva, whose protection runs through Chemours and DuPont. That is a three-deep indemnity chain on a liability with a 20-year tail, and Corteva’s own filing already flags “the solvency of DuPont, Dow and/or Chemours” as a reason its indemnification assets might be worth less than carried.

Vylor is clean. It is not hermetically sealed.

Valuation

Corteva has run +33.1% since announcing the breakup on October 1, 2025 ($61.47 → $81.79). At $81.79 it trades at 21.5–22.7× guided operating EPS and 13.6× FY26E EV/EBITDA — a large premium to the ag complex:

FMC deserves a second look, because it is what New Corteva is becoming. A pure-play crop protection company, market capitalization down to $1.4B against $3.9B of net debt, forward earnings at 6.8×. Management’s own commentary — Brazil pricing pressure, generic competition — describes the same forces that did that. New Corteva is far better positioned: larger, better capitalised, a real biologicals portfolio, and $3.56B of incoming cash. But the read-across is not comforting, and it is the reason the crop protection multiples below are struck where they are.

Splitting FY26E EBITDA — Vylor ~$2.75B, New Corteva ~$1.48B, summing to $4.23B against guidance of $4.1–4.3B — on the 1:1 ratio the pro formas assume:

Vylor carries the $4,479M of net debt. New Corteva receives the ~$3,560M and, on our arithmetic, lands near $1.7B net cash — an inference from Corteva’s consolidated position, not a disclosure.

On FY26 numbers the base case sits 7.5% below today’s price. You need Vylor at 16×+ before the sum beats the current quote.

The royalty ramp is the reason that is not the end of the analysis. Every figure above is struck on 2026, the year net royalty merely reaches zero. If the transition delivers even at half pace, the earnings base moves materially:

At $3.19B of EBITDA, 14× gives roughly $60/share for Vylor alone — the current bull case, on a base multiple, four years out.

Every row below FY2026 in that table assumes a generational handoff. As set out under Competitive Dynamics, the Enlist® traits that underwrite today’s royalty economics expire in 2031–2032 — before the 2035 target date. The ramp is not an extension of the current franchise; it depends on the next-generation traits whose patents run into the 2040s. Treat the 2030 and 2035 rows as conditional on a pipeline that has not yet been commercialised.

So the bull case has a mechanism, not just a re-rating. That is a meaningfully better argument than the one in the first draft of this analysis, which framed the upside as needing Vylor to be re-classified into a different sector. It does not. It needs the licensing transition to be real.

What it also means is that the entry price is doing very little work. Buying at $81.79 asks the buyer to fund a nine-year execution ramp at a full multiple, in a business whose organic revenue has compounded at 2.2%. The asset is excellent and the strategy is coherent. Neither makes today’s price attractive.

One caution worth keeping in view from our own cohort work: across 348 names, those that fell in their first quarter delivered a median total return of +27.6% against +96.4% for those that never dipped. On our data, waiting for post-spin weakness has not historically been the winning move — which argues against treating a first-year drawdown as the plan.

The setup going in

One detail worth recording: the August 14 amendment — disclosing a $5.6B capital structure and a $3.56B cash distribution — landed on a +1.2% day with 0.6× average volume. The most consequential document in the transaction moved nothing.

The family

Vylor is a third-generation spinoff: DowDuPont → Corteva (2019) → Vylor (2026). We hold the whole lineage, and the spread inside one corporate family is the widest of any cohort on the site.

Dow and Corteva were separated by eight weeks and have diverged by 264 percentage points. The IP-rich, high-margin businesses compounded; the commodity chemical business did not. Chemours — the one that took the legacy PFAS exposure — is the cautionary member, and its solvency is now an input into New Corteva’s balance sheet.

Vylor is unambiguously on the Corteva side of that line.

Rating

A−, and the provisional flag comes off.

The July grade was scored 3.80 with Financial Profile marked without a leverage input. That input now exists and it is favorable: 1.6–1.8× net leverage at a seasonal peak, an investment-grade target, a 4.12% weighted-average coupon, and dis-synergies cut to a quarter of the original estimate. The liability allocation and the management migration both read favorably for Vylor as well. Score stays 3.80; the dagger comes off.

What that grade is not saying is that the stock is cheap. It is a judgment on transaction quality — a clean two-way separation, the good assets and the whole management team on one side, the history on the other, moderate leverage, and a coherent strategic reason to exist. On price, Corteva has already captured most of the re-rating.

The asset is excellent. The entry is not obviously attractive. Both belong on the page.

What to watch